Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Project Oncology®Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Project Oncology®SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Project Oncology®Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Project Oncology®Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Project Oncology®Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Project Oncology®Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
- advertisement
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
CME/CEHER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
The Alloimmune Disorders of Pregnancy: Optimizing Fetal Outcomes Through Advances in Diagnosis and Treatment
CME/CEThe Alloimmune Disorders of Pregnancy: Optimizing Fetal Outcomes Through Advances in Diagnosis and Treatment
Why Are the Fetus and Placenta Not Rejected by the Mother? New Insights Into Maternal Anti-Fetal Rejection
CME/CEWhy Are the Fetus and Placenta Not Rejected by the Mother? New Insights Into Maternal Anti-Fetal Rejection
Parallels Between Kidney Transplantation and Maternal Anti-Fetal Rejection
CME/CEParallels Between Kidney Transplantation and Maternal Anti-Fetal Rejection
- advertisement
MIRASOL Insights in PROC: A Biomarker-Driven Approach
Project Oncology®MIRASOL Insights in PROC: A Biomarker-Driven Approach
Advancing Care in Pretreated HR+/HER2- mBC
Medical Industry FeatureAdvancing Care in Pretreated HR+/HER2- mBC
Supportive Care in Patients with Pretreated HR+/HER2- mBC
Medical Industry FeatureSupportive Care in Patients with Pretreated HR+/HER2- mBC
The Unmet Need in 1L HR+/HER2− Advanced Breast Cancer
Medical Industry FeatureThe Unmet Need in 1L HR+/HER2− Advanced Breast Cancer
New 3D MRI Technology Offers Enhanced Visibility During Fibroid Surgery
Medical Industry FeatureNew 3D MRI Technology Offers Enhanced Visibility During Fibroid Surgery
Clinical Decision Making for HER2 Low Metastatic Breast Cancer
Medical Industry FeatureClinical Decision Making for HER2 Low Metastatic Breast Cancer
- 12/11/2025
- 12/11/2025
- 12/11/2025
- 12/10/2025
- 12/10/2025
- 12/09/2025